/

Batteries & E-Mobility

/

SpringWorks Therapeutics

SpringWorks Therapeutics

SpringWorks Therapeutics

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

Stamford, Connecticut

·

Since 2017

SpringWorks Therapeutics is a biopharmaceutical company founded in 2017 and headquartered in Stamford, Connecticut, with 200–500 employees and estimated revenue of $100–250M. The company develops precision medicines for rare diseases, particularly rare tumors and cancers. It is a wholly-owned subsidiary of Merck KGaA. SpringWorks markets OGSIVEO for desmoid tumors and GOMEKLI for neurofibromatosis type 1-associated plexiform neurofibromas, with regulatory approvals in the United States and European markets.

SpringWorks Therapeutics

Verified Nov 2026

AT A GLANCE

Founded

2017

Headquarters

United States flag

Stamford, Connecticut

Employees

200-500

Ownership

SpringWorks Therapeutics at a glance

Revenue

$100-250M

Est. band

Employees

200-500

Founded

2017

Headquarters

Stamford, Connecticut

Industries

Automotive

Electric Vehicles

Medical

Overview

SpringWorks Therapeutics is a biopharmaceutical company founded in 2017 and headquartered in Stamford, Connecticut, with 200–500 employees and estimated revenue of $100–250M. The company develops precision medicines for rare diseases, particularly rare tumors and cancers. It is a wholly-owned subsidiary of Merck KGaA. SpringWorks markets OGSIVEO for desmoid tumors and GOMEKLI for neurofibromatosis type 1-associated plexiform neurofibromas, with regulatory approvals in the United States and European markets.

At a glance

Attribute

Detail

Founded

2017

Headquarters

Stamford, Connecticut

Employees

200-500

Revenue

$100-250M (estimated)

Primary capability

Batteries & E-Mobility

What SpringWorks Therapeutics makes

The company offers small molecule targeted oncology therapies with two FDA-approved commercial products and a clinical pipeline of candidates targeting solid tumors and hematological cancers.

Latest developments

Facilities

SpringWorks Therapeutics is headquartered in Stamford, Connecticut. Public sources also reference these locations:

Company details

SpringWorks became a subsidiary of Merck KGaA following completion of its acquisition in July 2025. SpringWorks Therapeutics was founded in 2017, has an estimated 200-500 employees, and is headquartered in Stamford, Connecticut.

Frequently asked questions

What does SpringWorks Therapeutics make?

SpringWorks Therapeutics is a biopharmaceutical company founded in 2017 and headquartered in Stamford, Connecticut, with 200–500 employees and estimated revenue of $100–250M. The company develops precision medicines for rare diseases, particularly rare tumors and cancers. It is a wholly-owned subsidiary of Merck KGaA. SpringWorks markets OGSIVEO for desmoid tumors and GOMEKLI for neurofibromatosis type 1-associated plexiform neurofibromas, with regulatory approvals in the United States and European markets.

Where is SpringWorks Therapeutics headquartered?

SpringWorks Therapeutics is headquartered in Stamford, Connecticut (100 Washington Blvd, Stamford, Connecticut, 06902).

When was SpringWorks Therapeutics founded?

SpringWorks Therapeutics was founded in 2017.

How big is SpringWorks Therapeutics?

SpringWorks Therapeutics has an estimated 200-500 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Stamford, Connecticut (HQ)Headquarters · United States
Stamford, Connecticut (HQ)100 Washington Blvd, Stamford, Connecticut, 06902, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.